CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
paricalcitol +1 moredrug
Likely dose
paricalcitol 1 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00428246
NCT00428246N/ACompleted
CompareCT.gov

Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol

Indiana University·interventional·Posted Jan 29, 2007·Updated Jun 3, 2009

In Brief

A clinical study evaluating paricalcitol and Placebo for Chronic Kidney Disease and 3 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the kidney and cause damage to the kidney. The purpose of this study is to determine if paricalcitol helps improve kidney injury, blood pressure control and kidney function in patients with chronic kidney disease. The study will last about 7 weeks and involves about 8 visits to the medical center.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
CountriesUnited States
CollaboratorsAbbott

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartNov 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.4 years ago

Interventions

paricalcitoldrug

1 mcg or 2 mcg for 4 weeks.

Placebodrug

Placebo